Stockreport

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF -- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL [Read more]